QPPV.COM KNOWLEDGE ASSESSMENT

Biosimilars: Regulatory Concepts, Development and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Biosimilars: Regulatory Concepts, Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A new adverse-event pattern is observed only with one biosimilar and is not established for the reference product. Which conclusion is most appropriate initially?

The pattern is automatically a biosimilar-specific causal risk The pattern should be evaluated as a potential concern, considering alternative explanations, biological plausibility, exposure and evidence from related products The pattern is irrelevant because the biosimilar was shown to be highly similar The absence of a reference-product signal proves a product-quality defect

Question 2 of 10 A cluster of reports occurs predominantly after a biosimilar manufacturing change and involves several batches. What is the most appropriate next step?

Conclude immediately that the manufacturing change caused the events Ignore the timing because manufacturing changes are addressed only by quality functions Connect the pharmacovigilance findings with quality, manufacturing, timing and batch information while maintaining a separate clinical safety assessment Reclassify all reports as reference-product events because the active substance is shared

Question 3 of 10 Which approach best reflects the article's three-level evidence model for evaluating a safety observation?

Use only biosimilar-specific reports and exclude reference-product information Pool all reports first and determine product attribution later Preserve biosimilar-specific evidence, use reference-product knowledge for context, and consider wider class evidence for appropriately defined hypotheses Use class-level evidence as proof that the biosimilar caused the event

Question 4 of 10 A patient develops a delayed immune-mediated event after switching from the reference product to a biosimilar. Which information is especially important for assessment?

Only the date on which the event was reported The complete exposure sequence, including previous product, switch date and timing of the event Only the biosimilar's marketing authorisation number The reference product's sales volume, without treatment chronology

Question 5 of 10 Why is product-level identification particularly important for biological products with the same active substance or international non-proprietary name?

It allows all products to be automatically assigned identical safety profiles It permits product-specific safety and immunogenicity concerns to be detected and evaluated It removes the need to collect clinical details in individual cases It is required only for products that have not undergone comparability assessment

Question 6 of 10 Which sequence best reflects the scientific logic of biosimilar development?

Large clinical efficacy trial, followed by limited analytical testing only if needed Reference-product selection, analytical and functional comparison, assessment of residual uncertainty, and targeted additional evidence where justified Post-authorisation signal detection, followed by selection of the reference product Same active substance confirmation, automatic indication extrapolation, and no further comparative assessment

Question 7 of 10 A biosimilar shows a measurable difference from the reference product in a quality attribute. What is the most scientifically appropriate next consideration?

Any measurable difference automatically prevents authorisation The difference should be interpreted in relation to the attribute's biological relevance, magnitude, consistency, function and other evidence The difference can be ignored because all biological products are inherently variable The difference proves that the products have different clinical safety profiles

Question 8 of 10 Why is the biosimilar development pathway not generally equivalent to the conventional generic pathway for chemically synthesised medicines?

Biological medicines are not subject to pharmacovigilance after authorisation Biological products can generally be reproduced exactly, making bioequivalence unnecessary Complex biological production can result in relevant structural and functional variability that requires a broader comparability assessment Generic medicines are assessed using clinical evidence, whereas biosimilars are assessed without any clinical evidence

Question 9 of 10 Which statement best describes the status of a proposed revision to an EMA biosimilar guideline during its consultation period?

It automatically becomes the applicable legal requirement when consultation opens It should be treated as final guidance for all regulatory decisions It is a proposal and does not replace the currently effective guideline until adopted and applicable It has no scientific relevance and should never be monitored

Question 10 of 10 Which statement best describes the pharmacovigilance interpretation of anti-drug antibodies?

Their detection is an adverse event by definition Their detection proves that the biosimilar is clinically inferior to the reference product Their significance depends on whether the immune response is associated with clinically meaningful effects such as altered exposure, reduced activity or hypersensitivity Their presence can be ignored after authorisation because immunogenicity is assessed only during development

Biosimilars: Regulatory Concepts, Development and Pharmacovigilance — Knowledge Assessment

Cookie Settings